Global Liposomal and Lipid-based Nanoparticle Drug Market Growth (Status and Outlook) 2022-2028
- LP 4891115
- 123 Pages
- March 2022
- Pharmaceuticals
The United States Liposomal and Lipid-based Nanoparticle Drug market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Liposomal and Lipid-based Nanoparticle Drug market, reaching US$ million by the year 2028. As for the Europe Liposomal and Lipid-based Nanoparticle Drug landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Liposomal and Lipid-based Nanoparticle Drug players cover Johnson & Johnson, Sun Pharmaceutical, CSPC, and Kinyond, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposomal and Lipid-based Nanoparticle Drug market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Liposomes Drugs
Lipid Nanoparticle Drugs
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital
Retail Pharmacy
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size 2017-2028
2.1.2 Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Liposomal and Lipid-based Nanoparticle Drug Segment by Type
2.2.1 Liposomes Drugs
2.2.2 Lipid Nanoparticle Drugs
2.3 Liposomal and Lipid-based Nanoparticle Drug Market Size by Type
2.3.1 Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2017-2022)
2.4 Liposomal and Lipid-based Nanoparticle Drug Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Liposomal and Lipid-based Nanoparticle Drug Market Size by Application
2.5.1 Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2017-2022)
3 Liposomal and Lipid-based Nanoparticle Drug Market Size by Player
3.1 Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Players
3.1.1 Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Players (2020-2022)
3.1.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2020-2022)
3.2 Global Liposomal and Lipid-based Nanoparticle Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Liposomal and Lipid-based Nanoparticle Drug by Regions
4.1 Liposomal and Lipid-based Nanoparticle Drug Market Size by Regions (2017-2022)
4.2 Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Growth (2017-2022)
4.3 APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Growth (2017-2022)
4.4 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Growth (2017-2022)
4.5 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth (2017-2022)
5 Americas
5.1 Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2017-2022)
5.2 Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022)
5.3 Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2017-2022)
6.2 APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022)
6.3 APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Liposomal and Lipid-based Nanoparticle Drug by Country (2017-2022)
7.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022)
7.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug by Region (2017-2022)
8.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022)
8.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.1 Global Liposomal and Lipid-based Nanoparticle Drug Forecast by Regions (2023-2028)
10.1.1 Global Liposomal and Lipid-based Nanoparticle Drug Forecast by Regions (2023-2028)
10.1.2 Americas Liposomal and Lipid-based Nanoparticle Drug Forecast
10.1.3 APAC Liposomal and Lipid-based Nanoparticle Drug Forecast
10.1.4 Europe Liposomal and Lipid-based Nanoparticle Drug Forecast
10.1.5 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Forecast
10.2 Americas Liposomal and Lipid-based Nanoparticle Drug Forecast by Country (2023-2028)
10.2.1 United States Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.2.2 Canada Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.2.3 Mexico Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.2.4 Brazil Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3 APAC Liposomal and Lipid-based Nanoparticle Drug Forecast by Region (2023-2028)
10.3.1 China Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.2 Japan Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.3 Korea Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.4 Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.5 India Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.3.6 Australia Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4 Europe Liposomal and Lipid-based Nanoparticle Drug Forecast by Country (2023-2028)
10.4.1 Germany Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4.2 France Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4.3 UK Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4.4 Italy Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.4.5 Russia Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Forecast by Region (2023-2028)
10.5.1 Egypt Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5.2 South Africa Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5.3 Israel Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5.4 Turkey Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.5.5 GCC Countries Liposomal and Lipid-based Nanoparticle Drug Market Forecast
10.6 Global Liposomal and Lipid-based Nanoparticle Drug Forecast by Type (2023-2028)
10.7 Global Liposomal and Lipid-based Nanoparticle Drug Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.1.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Johnson & Johnson Main Business Overview
11.1.5 Johnson & Johnson Latest Developments
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Information
11.2.2 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.2.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Sun Pharmaceutical Main Business Overview
11.2.5 Sun Pharmaceutical Latest Developments
11.3 CSPC
11.3.1 CSPC Company Information
11.3.2 CSPC Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.3.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 CSPC Main Business Overview
11.3.5 CSPC Latest Developments
11.4 Kinyond
11.4.1 Kinyond Company Information
11.4.2 Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.4.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Kinyond Main Business Overview
11.4.5 Kinyond Latest Developments
11.5 Teva
11.5.1 Teva Company Information
11.5.2 Teva Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.5.3 Teva Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Teva Main Business Overview
11.5.5 Teva Latest Developments
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Information
11.6.2 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Fudan-Zhangjiang Main Business Overview
11.6.5 Fudan-Zhangjiang Latest Developments
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Information
11.7.2 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.7.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 Zydus Cadila Main Business Overview
11.7.5 Zydus Cadila Latest Developments
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Information
11.8.2 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.8.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 TTY Biopharma Main Business Overview
11.8.5 TTY Biopharma Latest Developments
11.9 Pacira
11.9.1 Pacira Company Information
11.9.2 Pacira Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.9.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 Pacira Main Business Overview
11.9.5 Pacira Latest Developments
11.10 Luye Pharma
11.10.1 Luye Pharma Company Information
11.10.2 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.10.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 Luye Pharma Main Business Overview
11.10.5 Luye Pharma Latest Developments
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Information
11.11.2 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.11.4 Leadiant Biosciences Main Business Overview
11.11.5 Leadiant Biosciences Latest Developments
11.12 Ipsen
11.12.1 Ipsen Company Information
11.12.2 Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.12.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.12.4 Ipsen Main Business Overview
11.12.5 Ipsen Latest Developments
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Information
11.13.2 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.13.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.13.4 Sayre Therapeutics Main Business Overview
11.13.5 Sayre Therapeutics Latest Developments
11.14 Jazz
11.14.1 Jazz Company Information
11.14.2 Jazz Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.14.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.14.4 Jazz Main Business Overview
11.14.5 Jazz Latest Developments
11.15 Alnylam
11.15.1 Alnylam Company Information
11.15.2 Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.15.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.15.4 Alnylam Main Business Overview
11.15.5 Alnylam Latest Developments
11.16 Bausch Health
11.16.1 Bausch Health Company Information
11.16.2 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.16.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.16.4 Bausch Health Main Business Overview
11.16.5 Bausch Health Latest Developments
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Information
11.17.2 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.17.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.17.4 Acrotech Biopharma Main Business Overview
11.17.5 Acrotech Biopharma Latest Developments
11.18 Takeda
11.18.1 Takeda Company Information
11.18.2 Takeda Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.18.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.18.4 Takeda Main Business Overview
11.18.5 Takeda Latest Developments
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Information
11.19.2 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.19.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.19.4 Chiesi Farmaceutici Main Business Overview
11.19.5 Chiesi Farmaceutici Latest Developments
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Information
11.20.2 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Offered
11.20.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue, Gross Margin and Market Share (2020-2022)
11.20.4 Gilead Sciences Main Business Overview
11.20.5 Gilead Sciences Latest Developments
12 Research Findings and Conclusion
Table 1. Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Liposomes Drugs
Table 3. Major Players of Lipid Nanoparticle Drugs
Table 4. Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022) & ($ Millions)
Table 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2017-2022)
Table 7. Liposomal and Lipid-based Nanoparticle Drug Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022) & ($ Millions)
Table 9. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2017-2022)
Table 10. Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Players (2020-2022) & ($ Millions)
Table 11. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Player (2020-2022)
Table 12. Liposomal and Lipid-based Nanoparticle Drug Key Players Head office and Products Offered
Table 13. Liposomal and Lipid-based Nanoparticle Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Regions 2017-2022 & ($ Millions)
Table 17. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Regions (2017-2022)
Table 18. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2017-2022) & ($ Millions)
Table 19. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Country (2017-2022)
Table 20. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022) & ($ Millions)
Table 21. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2017-2022)
Table 22. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022) & ($ Millions)
Table 23. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2017-2022)
Table 24. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2017-2022) & ($ Millions)
Table 25. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Region (2017-2022)
Table 26. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022) & ($ Millions)
Table 27. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2017-2022)
Table 28. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022) & ($ Millions)
Table 29. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2017-2022)
Table 30. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2017-2022) & ($ Millions)
Table 31. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Country (2017-2022)
Table 32. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022) & ($ Millions)
Table 33. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2017-2022)
Table 34. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022) & ($ Millions)
Table 35. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2017-2022)
Table 36. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2017-2022) & ($ Millions)
Table 37. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Region (2017-2022)
Table 38. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type (2017-2022)
Table 40. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application (2017-2022)
Table 42. Key Market Drivers & Growth Opportunities of Liposomal and Lipid-based Nanoparticle Drug
Table 43. Key Market Challenges & Risks of Liposomal and Lipid-based Nanoparticle Drug
Table 44. Key Industry Trends of Liposomal and Lipid-based Nanoparticle Drug
Table 45. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 46. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share Forecast by Regions (2023-2028)
Table 47. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 48. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share Forecast by Type (2023-2028)
Table 49. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 50. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share Forecast by Application (2023-2028)
Table 51. Johnson & Johnson Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 52. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 53. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 54. Johnson & Johnson Main Business
Table 55. Johnson & Johnson Latest Developments
Table 56. Sun Pharmaceutical Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 57. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 58. Sun Pharmaceutical Main Business
Table 59. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 60. Sun Pharmaceutical Latest Developments
Table 61. CSPC Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 62. CSPC Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 63. CSPC Main Business
Table 64. CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 65. CSPC Latest Developments
Table 66. Kinyond Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 67. Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 68. Kinyond Main Business
Table 69. Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 70. Kinyond Latest Developments
Table 71. Teva Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 72. Teva Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 73. Teva Main Business
Table 74. Teva Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 75. Teva Latest Developments
Table 76. Fudan-Zhangjiang Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 77. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 78. Fudan-Zhangjiang Main Business
Table 79. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 80. Fudan-Zhangjiang Latest Developments
Table 81. Zydus Cadila Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 82. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 83. Zydus Cadila Main Business
Table 84. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 85. Zydus Cadila Latest Developments
Table 86. TTY Biopharma Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 87. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 88. TTY Biopharma Main Business
Table 89. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 90. TTY Biopharma Latest Developments
Table 91. Pacira Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 92. Pacira Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 93. Pacira Main Business
Table 94. Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 95. Pacira Latest Developments
Table 96. Luye Pharma Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 97. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 98. Luye Pharma Main Business
Table 99. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 100. Luye Pharma Latest Developments
Table 101. Leadiant Biosciences Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 102. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 103. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 104. Leadiant Biosciences Main Business
Table 105. Leadiant Biosciences Latest Developments
Table 106. Ipsen Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 107. Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 108. Ipsen Main Business
Table 109. Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 110. Ipsen Latest Developments
Table 111. Sayre Therapeutics Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 112. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 113. Sayre Therapeutics Main Business
Table 114. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 115. Sayre Therapeutics Latest Developments
Table 116. Jazz Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 117. Jazz Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 118. Jazz Main Business
Table 119. Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 120. Jazz Latest Developments
Table 121. Alnylam Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 122. Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 123. Alnylam Main Business
Table 124. Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 125. Alnylam Latest Developments
Table 126. Bausch Health Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 127. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 128. Bausch Health Main Business
Table 129. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 130. Bausch Health Latest Developments
Table 131. Acrotech Biopharma Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 132. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 133. Acrotech Biopharma Main Business
Table 134. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 135. Acrotech Biopharma Latest Developments
Table 136. Takeda Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 137. Takeda Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 138. Takeda Main Business
Table 139. Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 140. Takeda Latest Developments
Table 141. Chiesi Farmaceutici Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 142. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 143. Chiesi Farmaceutici Main Business
Table 144. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 145. Chiesi Farmaceutici Latest Developments
Table 146. Gilead Sciences Details, Company Type, Liposomal and Lipid-based Nanoparticle Drug Area Served and Its Competitors
Table 147. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Offered
Table 148. Gilead Sciences Main Business
Table 149. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 150. Gilead Sciences Latest Developments
List of Figures
Figure 1. Liposomal and Lipid-based Nanoparticle Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type in 2021
Figure 7. Liposomal and Lipid-based Nanoparticle Drug in Hospital
Figure 8. Global Liposomal and Lipid-based Nanoparticle Drug Market: Hospital (2017-2022) & ($ Millions)
Figure 9. Liposomal and Lipid-based Nanoparticle Drug in Retail Pharmacy
Figure 10. Global Liposomal and Lipid-based Nanoparticle Drug Market: Retail Pharmacy (2017-2022) & ($ Millions)
Figure 11. Liposomal and Lipid-based Nanoparticle Drug in Other
Figure 12. Global Liposomal and Lipid-based Nanoparticle Drug Market: Other (2017-2022) & ($ Millions)
Figure 13. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2021
Figure 14. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Player in 2021
Figure 15. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Regions (2017-2022)
Figure 16. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size 2017-2022 ($ Millions)
Figure 17. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size 2017-2022 ($ Millions)
Figure 18. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size 2017-2022 ($ Millions)
Figure 19. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size 2017-2022 ($ Millions)
Figure 20. Americas Liposomal and Lipid-based Nanoparticle Drug Value Market Share by Country in 2021
Figure 21. Americas Liposomal and Lipid-based Nanoparticle Drug Consumption Market Share by Type in 2021
Figure 22. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2021
Figure 23. United States Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 24. Canada Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 25. Mexico Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 26. Brazil Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 27. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Region in 2021
Figure 28. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2021
Figure 29. China Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 30. Japan Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 31. Korea Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 32. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 33. India Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 34. Australia Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 35. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Country in 2021
Figure 36. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type in 2021
Figure 37. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2021
Figure 38. Germany Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 39. France Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 40. UK Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 41. Italy Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 42. Russia Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 43. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Region in 2021
Figure 44. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Type in 2021
Figure 45. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Market Share by Application in 2021
Figure 46. Egypt Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 47. South Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 48. Israel Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 49. Turkey Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 50. GCC Country Liposomal and Lipid-based Nanoparticle Drug Market Size Growth 2017-2022 ($ Millions)
Figure 51. Americas Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 52. APAC Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 53. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 54. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 55. United States Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 56. Canada Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 57. Mexico Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 58. Brazil Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 59. China Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 60. Japan Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 61. Korea Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 62. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 63. India Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 64. Australia Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 65. Germany Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 66. France Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 67. UK Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 68. Italy Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 69. Russia Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 70. Spain Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 71. Egypt Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 72. South Africa Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 73. Israel Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 74. Turkey Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Figure 75. GCC Countries Liposomal and Lipid-based Nanoparticle Drug Market Size 2023-2028 ($ Millions)
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
